AM630 behaves as a protean ligand at the human cannabinoid CB 2 receptor

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2561-2574

  Bolognini, Daniele ^a,b   Cascio, Maria Grazia ^a   Parolaro, Daniela ^b   Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

9 tetrahydrocannabivarin; AM630; Cannabinoid CB 2 receptor; CP55940; Inverse agonism; Neutral antagonism; Protean ligand; R (+) WIN55212; SR144528; Two state model of agonism and inverse agonism

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CYCLIC AMP; DELTA 9 TETRAHYDROCANNABIVARIN; FORSKOLIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL MEMBRANE; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; WHOLE CELL;

ANIMALS; BENZOXAZINES; BORNANES; CANNABINOIDS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOHEXANOLS; HUMANS; INDOLES; LIGANDS; MORPHOLINES; NAPHTHALENES; PYRAZOLES; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB2; TETRAHYDROCANNABINOL;

EID: 84859051393     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01503.x     Document Type: Article

References (24)

1. Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. 2 receptor antagonist. Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, P4-28.
3. 9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 160: 677-687.
4. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
5. Colquhoun D (1971). Lectures on Biostatistics. Oxford Univ Press: Oxford.
6. Gobeil F, Fortier A, Zhu T, Bossolasco M, Leduc M, Grandbois M et al. (2006). G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol 84: 287-297. (Pubitemid 44481092)
7. Hall DA (2000). Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58: 1412-1423.
8. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202. (Pubitemid 34575709)
9. Kenakin T (1997). Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott-Raven: Philadelphia, PA.
10. Kenakin T (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15: 598-611.
11. Leff P (1995). The two-state model of receptor activation. Trends Pharmacol Sci 16: 89-97.
12. Lunn CA (2010). Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonists. Curr Top Med Chem 10: 768-778.
13. 2receptor inverse agonists. Br J Pharmacol 153: 226-239.
14. 2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. Br J Pharmacol 158: 382-391.
15. Pertwee RG (2005). Pharmacological actions of cannabinoids. In: Pertwee RG (ed.). Cannabinoids. Springer-Verlag: Heidelberg, pp. 1-51.
16. Handbook Exp Pharmacol 168: 1-51.
17. Pertwee RG, Ross RA, Craib SJ, Thomas A (2002). (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456: 99-106. (Pubitemid 35351742)
18. 2. Pharmacol Rev 62: 588-631.
19. 2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126: 665-672.
20. Ross RA, Gibson TM, Stevenson LA, Saha B, Crocker P, Razdan RK et al. (1999b). Structural determinants of the partial agonist-inverse agonist properties of 6&πριμε;-azidohex- 2&πριμε;-yne-Δ8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol 128: 735-743. (Pubitemid 29504767)
21. 1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J 22: 2311-2322.
22. Scandroglio P, Brusa R, Lozza G, Mancini I, Petro R, Reggiani A et al. (2010). Evaluation of cannabinoid receptor 2 and metabotropic glutamate receptor 1 functional responses using a cell impedance-based technology. J Biomol Screen 15: 1238-1247.
23. 2 receptor antagonist. Br J Pharmacol 146: 917-926.
24. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK et al. (2006). In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 149: 145-154. (Pubitemid 44360095)